Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029349 | 0.88 | RXFP1 (0.61) | POLBRXFP1MAPTTP53LMNA | |
| SCHEMBL24029355 | 0.80 | POLB (0.50) | POLBRXFP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL24209799 | 0.75 | RXFP1 (0.82) | POLBRXFP1MAPTTP53LMNA | |
| SCHEMBL24029049 | 0.74 | POLB (0.66) | POLBALDH1A1 | |
| SCHEMBL24029354 | 0.73 | POLB (0.41) | POLBMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15022926 | 0.64 | LIPG (0.68) | — | |
| SCHEMBL6945571 | 0.63 | HTT (0.50) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL3868831 | 0.63 | GAA (0.91) | POLBMAPTTP53LMNAGAA | |
| SCHEMBL23409688 | 0.63 | HTT (0.47) | MAPTSMN1; SMN2HPGDGAAALDH1A1 | |
| SCHEMBL24209791 | 0.62 | ALDH1A1 (0.66) | POLBLMNASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | POLB 1121/4885RXFP1 4623/4885MAPT 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.